FI990875A0 - CD4-specifik rekombinantantikropp - Google Patents

CD4-specifik rekombinantantikropp

Info

Publication number
FI990875A0
FI990875A0 FI990875A FI990875A FI990875A0 FI 990875 A0 FI990875 A0 FI 990875A0 FI 990875 A FI990875 A FI 990875A FI 990875 A FI990875 A FI 990875A FI 990875 A0 FI990875 A0 FI 990875A0
Authority
FI
Finland
Prior art keywords
antibody
pref
derived
chain
cdr
Prior art date
Application number
FI990875A
Other languages
English (en)
Finnish (fi)
Other versions
FI990875A (sv
FI109768B (sv
Inventor
Linda Kay Jolliffe
Robert Allan Zivin
Virginia Lee Pulito
John Robert Adair
Diljeet Singh Athwal
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10668300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI990875(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of FI990875A publication Critical patent/FI990875A/sv
Publication of FI990875A0 publication Critical patent/FI990875A0/sv
Application granted granted Critical
Publication of FI109768B publication Critical patent/FI109768B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
FI990875A 1989-12-21 1999-04-19 CD4-specifik rekombinantantikropp FI109768B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB898928874A GB8928874D0 (en) 1989-12-21 1989-12-21 Humanised antibodies
GB8928874 1989-12-21
PCT/GB1990/002015 WO1991009966A1 (en) 1989-12-21 1990-12-21 Cd4 specific recombinant antibody
GB9002015 1990-12-21
FI913932 1991-08-20
FI913932A FI108917B (sv) 1989-12-21 1991-08-20 Förfarande för framställning av en terapeutiskt användbar CD4-specifik rekombinantantikropp

Publications (3)

Publication Number Publication Date
FI990875A FI990875A (sv) 1999-04-19
FI990875A0 true FI990875A0 (sv) 1999-04-19
FI109768B FI109768B (sv) 2002-10-15

Family

ID=10668300

Family Applications (4)

Application Number Title Priority Date Filing Date
FI913927A FI108776B (sv) 1989-12-21 1991-08-20 Förfarande för att producera en antantikroppsmolekyl bearbetad med anti-CD3-CDR-graft
FI913926A FI108777B (sv) 1989-12-21 1991-08-20 Förfarande för att producera en antikroppsmolekyl bearbetad med CDR-graft
FI913932A FI108917B (sv) 1989-12-21 1991-08-20 Förfarande för framställning av en terapeutiskt användbar CD4-specifik rekombinantantikropp
FI990875A FI109768B (sv) 1989-12-21 1999-04-19 CD4-specifik rekombinantantikropp

Family Applications Before (3)

Application Number Title Priority Date Filing Date
FI913927A FI108776B (sv) 1989-12-21 1991-08-20 Förfarande för att producera en antantikroppsmolekyl bearbetad med anti-CD3-CDR-graft
FI913926A FI108777B (sv) 1989-12-21 1991-08-20 Förfarande för att producera en antikroppsmolekyl bearbetad med CDR-graft
FI913932A FI108917B (sv) 1989-12-21 1991-08-20 Förfarande för framställning av en terapeutiskt användbar CD4-specifik rekombinantantikropp

Country Status (21)

Country Link
US (10) US5929212A (sv)
EP (5) EP0626390B1 (sv)
JP (4) JPH04505398A (sv)
KR (3) KR100191152B1 (sv)
AT (4) ATE124459T1 (sv)
AU (4) AU646009B2 (sv)
BG (1) BG60462B1 (sv)
BR (1) BR9007197A (sv)
CA (3) CA2050479C (sv)
DE (4) DE69033857T2 (sv)
DK (4) DK0626390T3 (sv)
ES (4) ES2165864T3 (sv)
FI (4) FI108776B (sv)
GB (4) GB8928874D0 (sv)
GR (2) GR3017734T3 (sv)
HU (4) HUT60786A (sv)
NO (5) NO913229L (sv)
RO (3) RO114980B1 (sv)
RU (1) RU2112037C1 (sv)
WO (3) WO1991009968A1 (sv)
ZA (1) ZA9110129B (sv)

Families Citing this family (1297)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69032484T4 (de) * 1989-10-27 1999-09-16 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
US6750325B1 (en) * 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US6399062B1 (en) * 1990-11-06 2002-06-04 The United States Of America As Represented By The Secretary Of The Navy Murine monoclonal antibody protective against Plasmodium vivax malaria
JPH05505112A (ja) * 1990-11-27 1993-08-05 バイオジェン，インコーポレイテッド Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9104498D0 (en) * 1991-03-04 1991-04-17 Ks Biomedix Ltd Antibody
DE07006112T1 (de) * 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
WO1992019759A1 (en) * 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US6699472B2 (en) 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
EP0528767B1 (en) * 1991-08-21 2000-01-12 Novartis AG Antibody derivatives
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
AU3236793A (en) * 1991-12-12 1993-07-19 Berlex Laboratories, Inc. Recombinant and chimeric antibodies to c-erbB-2
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
DE69334255D1 (de) * 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) * 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
EP0563487A1 (en) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
DE4225853A1 (de) * 1992-08-05 1994-02-10 Behringwerke Ag Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
WO1995013094A1 (en) * 1993-11-10 1995-05-18 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
EP0729976A1 (en) * 1993-11-19 1996-09-04 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
WO1995023865A1 (en) * 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
AU707440B2 (en) 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin
WO1995031546A1 (en) * 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
AU4270596A (en) * 1994-12-23 1996-07-19 Celltech Therapeutics Limited Human phosphodiesterase type ivc, and its production and use
WO1996020219A2 (en) * 1994-12-28 1996-07-04 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1
US6949244B1 (en) * 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US5795961A (en) * 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
DE69627665T2 (de) * 1995-05-18 2004-02-19 Ortho-Mcneil Pharmaceutical, Inc. Induktion von immunologischer toleranz unter verwendung von nicht-zellmengeverringernden anti-cd4-antikoepern
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
DK0833911T3 (da) * 1995-06-07 2004-08-30 Ortho Mcneil Pharm Inc CDR-transplanterede anti-vævsfaktorantistoffer og fremgangsmåder til anvendelse deraf
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
AU6113396A (en) * 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens
DE19543039C1 (de) * 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
SI9720020B (en) * 1996-02-09 2001-12-31 Basf Ag Human antibodies that bind human TNF alpha
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
EP0909277B2 (en) 1996-06-07 2008-12-24 Poniard Pharmaceuticals, Inc. Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0941345A2 (en) * 1996-09-20 1999-09-15 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6737057B1 (en) * 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
CN1624128A (zh) * 1997-03-17 2005-06-08 人类基因组科学公司 包含死亡结构域的受体－5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE69829891T2 (de) * 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
PT1787999E (pt) * 1997-04-07 2010-11-11 Genentech Inc Anticorpos anti-vegf
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
CN1277632A (zh) * 1997-10-03 2000-12-20 中外制药株式会社 天然人源化抗体
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
AU3072799A (en) 1998-03-19 1999-10-11 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
ES2364266T3 (es) 1998-04-03 2011-08-30 Chugai Seiyaku Kabushiki Kaisha Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado.
JP4169478B2 (ja) 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
CA2327505A1 (en) * 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
CA2345356C (en) 1998-10-06 2012-10-02 Mark Aaron Emalfarb Transformation system in the field of filamentous fungal hosts
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
IL143266A0 (en) 1998-11-27 2002-04-21 Darwin Discovery Ltd Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
WO2001021215A1 (en) * 1999-09-22 2001-03-29 Ortho-Mcneil Pharmaceutical, Inc. Cell based assay
ES2301491T3 (es) * 1999-09-30 2008-07-01 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo humano de trasplante con region de determinacion de la complementariedad contra gangliosido gd3 y derivados del anticuerpo contra gangliosido gd3.
US6342587B1 (en) * 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
CU22921A1 (es) * 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6656467B2 (en) * 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
EP1783227A1 (en) * 2000-02-03 2007-05-09 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
CA2399080C (en) * 2000-02-03 2013-05-21 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
AU2001234953B2 (en) 2000-02-11 2006-03-16 Biogen Ma Inc. Heterologous polypeptide of the tnf family
CN101670105B (zh) 2000-02-24 2014-08-06 华盛顿大学 螯合淀粉样蛋白β肽的人源化抗体
DK1259547T3 (da) * 2000-03-01 2012-10-15 Medimmune Inc Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
CA2401993A1 (en) * 2000-03-02 2001-09-07 Abgenix, Inc. Human monoclonal antibodies against oxidized ldl receptor and pharmaceutical uses thereof
EP1267926A2 (en) 2000-03-17 2003-01-02 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001248840B2 (en) 2000-04-21 2005-06-09 Fuso Pharmaceutical Industries, Ltd. Novel collectins
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
NZ522700A (en) 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US7060802B1 (en) 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
GEP20063752B (en) 2000-10-13 2006-02-27 Biogen Inc Humanized Anti-LT-Beta-R Antibodies
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
JP4434580B2 (ja) 2000-11-28 2010-03-17 メディミューン，エルエルシー 予防及び治療のために抗ｒｓｖ抗体を投与／処方する方法
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
HUP0302525A2 (hu) 2001-01-05 2003-10-28 Abgenix, Inc. Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002062850A2 (en) * 2001-02-02 2002-08-15 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
JP2005503116A (ja) 2001-02-09 2005-02-03 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
CN100404673C (zh) 2001-02-19 2008-07-23 默克专利有限公司 鉴定t细胞表位的方法及制备具有降低的免疫原性的分子的用途
EP1411962B1 (en) * 2001-03-15 2011-01-19 Neogenix Oncology, Inc. Monoclonal antibody therapy for pancreas cancer
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
NZ529359A (en) 2001-05-25 2007-04-27 Human Genome Sciences Inc Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
JP4729717B2 (ja) * 2001-08-03 2011-07-20 株式会社医学生物学研究所 ＧＭ１ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするＤＮＡ
DK1944040T3 (da) 2001-08-17 2012-10-29 Univ Washington Analysefremgangsmåde for Alzheimers sygdom
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
WO2003025124A2 (en) * 2001-09-14 2003-03-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immunoglobulin having particular framework scaffold and methods of making and using
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
CA2463616C (en) * 2001-10-15 2011-07-12 Immunomedics, Inc. Affinity enhancement agents
ATE524196T1 (de) * 2001-10-16 2011-09-15 Macrogenics West Inc An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
WO2003063768A2 (en) * 2001-10-25 2003-08-07 Euro-Celtique S.A. Compositions and methods directed to anthrax toxin
WO2003048729A2 (en) * 2001-12-03 2003-06-12 Abgenix, Inc. Discovery of therapeutic products
AU2002357779A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Identification of high affinity molecules by limited dilution screening
ATE395413T1 (de) * 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1499352A4 (en) 2002-04-12 2006-10-11 Medimmune Inc ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
CA2484121A1 (en) 2002-05-01 2003-11-13 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
AU2012244218C1 (en) * 2002-05-02 2016-12-15 Wyeth Holdings Llc. Calicheamicin derivative-carrier conjugates
LT1507556T (lt) 2002-05-02 2016-10-10 Wyeth Holdings Llc Kalicheamicino darinio ir nešiklio konjugatai
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP1534753B1 (en) 2002-05-28 2011-08-03 UCB Pharma, S.A. Peg positional isomer of an anti-tnfalpha antibody (cdp870)
EP1531848A4 (en) 2002-06-10 2007-03-28 Vaccinex Inc DIFFERENTIAL EXPRESSED GENE IN BREAST AND BLADDER CANCER AND CODED POLYPEPTIDE
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2003243651B2 (en) 2002-06-17 2008-10-16 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Specificity grafting of a murine antibody onto a human framework
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
NZ537965A (en) 2002-07-01 2008-04-30 Biogen Idec Inc Humanized anti-lymphotoxin beta receptor antibodies
NZ555692A (en) * 2002-07-19 2009-02-28 Abbott Biotech Ltd Treatment of TNF alpha related disorders
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
US8071321B2 (en) 2002-08-29 2011-12-06 Cytocure Llc Methods for up-regulating antigen expression in tumors
US7803372B2 (en) 2002-10-08 2010-09-28 Immunomedics, Inc. Antibody therapy
RS20050300A (en) 2002-10-16 2007-08-03 Euro-Celtique S.A., Antibodies that bind cell-associated ca 125/0772p and methods of use thereof
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2003304203A1 (en) * 2002-10-29 2005-01-04 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
WO2004039845A1 (en) * 2002-10-31 2004-05-13 Universita'degli Studi Di Roma 'la Sapienza' Antimicrobial lipase antibodies their nucleotide and aminoacid sequences and uses thereof
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
US7405061B2 (en) * 2002-11-13 2008-07-29 Raven Biotechnologies, Inc. Antigen PIPA and antibodies that bind thereto
EP2258724A1 (en) 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulating immune responses using multimerized anti-CD83 antibodies
JP4741242B2 (ja) 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
ES2388280T3 (es) 2002-12-20 2012-10-11 Abbott Biotherapeutics Corp. Anticuerpos que reaccionan frente a GPR64 y utilización de los mismos
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
CA2513113A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2004069182A2 (en) * 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
WO2004071408A2 (en) * 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP2241330A1 (en) 2003-02-14 2010-10-20 The Curators Of The University Of Missouri Contraceptive methods and compositions related to proteasomal interference
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
RS54160B1 (sr) 2003-03-19 2015-12-31 Biogen Idec Ma Inc. Protein koji se vezuje za nogo receptor
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
EP1631312B1 (en) 2003-04-23 2008-09-10 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
EP1641827A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2532250A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
RS53476B (en) * 2003-07-18 2014-12-31 Amgen Fremont Inc. Hepatocyte Growth Factor Binders
WO2005009369A2 (en) * 2003-07-21 2005-02-03 Immunogen, Inc. A ca6 antigen-specific cytotoxic conjugate and methods of using the same
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
EP1668111A4 (en) 2003-08-08 2008-07-02 Genenews Inc OSTEOARTHRITIS BIOMARKERS AND USES THEREOF
MXPA06001634A (es) 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
WO2005042743A2 (en) 2003-08-18 2005-05-12 Medimmune, Inc. Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1660534A2 (en) * 2003-08-22 2006-05-31 MedImmune, Inc. Humanization of antibodies
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
DK1673398T3 (da) 2003-10-16 2011-04-18 Micromet Ag Multispecifikke, deimmuniserede CD3-bindere
WO2005040395A1 (en) 2003-10-22 2005-05-06 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
DK1687338T3 (da) 2003-11-07 2011-02-07 Ablynx Nv Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf
EP1695093A1 (en) * 2003-12-05 2006-08-30 multimmune GmbH Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases
SG10201900535UA (en) 2003-12-23 2019-02-27 Genentech Inc Novel anti-il 13 antibodies and uses thereof
PT2311873T (pt) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
US20070280950A1 (en) 2004-01-19 2007-12-06 Medical And Biological Laboratories Co., Ltd. Inflammatory Cytokine Inhibitors
MXPA06009072A (es) 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
AU2005212369B2 (en) 2004-02-10 2011-06-23 Musc Foundation For Research Development Inhibition of factor B, the alternative complement pathway and methods related thereto
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2005097184A2 (en) 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
DK2662390T3 (da) 2004-06-21 2017-11-06 Squibb & Sons Llc Interferon alpha receptor 1-antistoffer og anvendelse heraf
CA2572193A1 (en) 2004-06-24 2006-01-05 Biogen Idec Ma Inc. Treatment of conditions involving oligodendrocytes with sp35 based agents
JP2008504289A (ja) * 2004-06-25 2008-02-14 メディミューン，インコーポレーテッド 部位特異的突然変異誘発による哺乳動物細胞における組換え抗体の産生の増加
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
EP1802341A1 (en) 2004-07-16 2007-07-04 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
EP2476427B1 (en) * 2004-08-02 2018-01-17 Zenyth Operations PTY. Ltd. A method of treating cancer comprising a VEGF-B antagonist
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
EP1791568B1 (en) 2004-08-16 2012-08-15 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801
US20060045877A1 (en) 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
US7700720B2 (en) 2004-09-21 2010-04-20 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP1807111A4 (en) * 2004-10-08 2009-05-27 Abbott Biotech Ltd SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP4881874B2 (ja) 2004-12-06 2012-02-22 協和発酵キリン株式会社 インフルエンザｍ２タンパク質に対するヒトモノクローナル抗体及びその生産方法及びその使用
TW200636066A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
PE20061401A1 (es) * 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
JP5855326B2 (ja) 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス 抗ｋｉｒ組み合わせ治療および方法
CN101495498B (zh) 2005-02-07 2013-09-18 基因信息公司 轻度骨关节炎生物标志物及其用途
AU2006214121B9 (en) 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
EP1858545A2 (en) 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
CA2601400A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
CA2605024C (en) 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
AU2006236225C1 (en) 2005-04-19 2013-05-02 Seagen Inc. Humanized anti-CD70 binding agents and uses thereof
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
EP2221316A1 (en) 2005-05-05 2010-08-25 Duke University Anti-CD19 antibody therapy for autoimmune disease
CN101198624B (zh) 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
WO2006121159A1 (ja) * 2005-05-12 2006-11-16 Kyowa Hakko Kogyo Co., Ltd. Cd10に特異的に反応するヒト型cdr移植抗体およびその抗体断片
CN101500607B (zh) 2005-05-16 2013-11-27 阿布维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
EP1888640B1 (en) 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
CA2606576A1 (en) 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
PL3415535T3 (pl) 2005-05-20 2021-06-14 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
US7393919B2 (en) 2005-05-25 2008-07-01 Cure Dm, Inc. Peptides, derivatives and analogs thereof, and methods of using same
CN101227924A (zh) 2005-05-26 2008-07-23 科罗拉多大学评议会 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
NZ563580A (en) * 2005-06-07 2010-09-30 Esbatech An Alcon Biomedical R Stable and soluble antibodies inhibiting TNFaplha
CA2613512A1 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
CN103172737A (zh) 2005-06-30 2013-06-26 Abbvie公司 Il-12/p40结合蛋白
EP2238986A3 (en) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35 antibodies and uses thereof
WO2007008604A2 (en) 2005-07-08 2007-01-18 Bristol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
SG10201504917PA (en) 2005-07-11 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
US8652469B2 (en) 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
DK1919503T3 (en) 2005-08-10 2014-12-15 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods of use thereof
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007037430A1 (ja) 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. Ｔ細胞接着分子およびそれに対する抗体
WO2007039256A2 (de) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
CA2625440C (en) 2005-10-11 2023-06-13 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
US8239136B2 (en) 2005-10-21 2012-08-07 Genenews Inc. Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
KR20180002911A (ko) 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
NZ568705A (en) 2005-11-04 2012-07-27 Biogen Idec Inc Methods for promoting neurite outgrowth and survival of dopaminergic neurons
NZ568762A (en) 2005-11-07 2011-11-25 Scripps Research Inst Use of an inhibitor of tissue factor signaling in the manufacture of a medcament for inhibiting or suppressing tissue factor/tissue factor VIIa signaling involving protease activated receptor 2 in a mammal
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
NZ598421A (en) 2005-12-02 2013-11-29 Biogen Idec Inc Treatment of Conditions Involving Demyelination
CN101356194B (zh) 2005-12-09 2013-06-12 Ucb医药有限公司 对人il-6具有特异性的抗体分子
GB0525214D0 (en) * 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
DK1976880T3 (en) 2005-12-21 2016-09-26 Amgen Res (Munich) Gmbh Pharmaceutical compositions with resistance to soluble cea
AU2007207341B2 (en) 2006-01-20 2012-05-10 Women's & Children's Health Research Institute Incorporated Method of treatment, prophylaxis and diagnosis of pathologies of the bone
UY30097A1 (es) 2006-01-20 2007-08-31 Atugen Ag Usos terapeuticos de inhibidores de rtp801
US8669345B2 (en) 2006-01-27 2014-03-11 Biogen Idec Ma Inc. Nogo receptor antagonists
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
NZ571208A (en) 2006-03-10 2011-12-22 Wyeth Corp Anti-5T4 antibodies and uses thereof
SI1999152T1 (sl) 2006-03-27 2013-02-28 Medimmune Limited Vezni äślen za gm-csf receptor
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
US9101670B2 (en) 2006-04-07 2015-08-11 Nektar Therapeutics Conjugates of an anti-TNF-α antibody
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
CA2653387A1 (en) * 2006-06-06 2007-12-21 Tolerrx, Inc. Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP2037961B1 (en) 2006-06-14 2015-11-11 MacroGenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP2029173B1 (en) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc riib-specific antibodies and methods of use thereof
JP5829004B2 (ja) 2006-06-30 2015-12-09 ノボ・ノルデイスク・エー／エス 抗ｎｋｇ２ａ抗体とその使用
TWI527603B (zh) 2006-06-30 2016-04-01 艾伯維生物技術有限責任公司 自動注射裝置
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
GB0613209D0 (en) 2006-07-03 2006-08-09 Ucb Sa Methods
KR101528939B1 (ko) 2006-07-18 2015-06-15 사노피 암 치료를 위한 ｅｐｈａ2에 대한 길항제 항체
EP2046826B1 (en) 2006-07-24 2011-09-14 Biorexis Pharmaceutical Corporation Exendin fusion proteins
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
KR101437188B1 (ko) 2006-08-04 2014-10-02 노바르티스 아게 Ｅｐｈｂ3-특이적 항체 및 이의 용도
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
ME00588A (en) 2006-08-18 2011-12-20 Prlr-specific antibody and uses thereof
MY162024A (en) 2006-08-28 2017-05-31 La Jolla Inst Allergy & Immunology Antagonistic human light-specific human monoclonal antibodies
RU2009111884A (ru) 2006-09-01 2010-10-10 Займоджинетикс, Инк. (Us) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
UA115964C2 (uk) 2006-09-08 2018-01-25 Еббві Айрленд Анлімітед Компані Інтерлейкін-13-зв'язувальний білок
AU2007313300A1 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR101154276B1 (ko) 2006-11-17 2012-07-10 사이단호진한다이비세이부쯔뵤우겐큐우카이 신경 신장 촉진제 및 신장 억제제
WO2008064306A2 (en) 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
ES2476798T3 (es) 2006-11-27 2014-07-15 Patrys Limited Nueva diana de p�ptido glucosilado en células neopl�sicas
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
EP2505651A3 (en) 2006-12-10 2013-01-09 Dyadic International, Inc. Isolated fungus with reduced protease activity
CL2007003661A1 (es) 2006-12-18 2008-07-18 Genentech Inc Regiones de cadena pesada variable y liviana variable; acidos nucleicos que las codifican; metodo de produccion; anticuerpos anti-notch3 que las comprenden; y uso de los anticuerpos para tratar enfermedades relacionadas con el receptor notch3.
EP2557090A3 (en) 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
AU2008205244B2 (en) 2007-01-09 2013-02-07 Biogen Ma Inc. Sp35 antibodies and uses thereof
ES2825718T3 (es) 2007-02-01 2021-05-17 Univ Der Johannes Gutenberg Univ Mainz Activación específica de una célula T reguladora y su uso para el tratamiento del asma, enfermedades alérgicas, enfermedades autoinmunes, rechazo de injertos y para la inducción de tolerancia
US8168415B2 (en) 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
EP1958645A1 (en) 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
US8114606B2 (en) 2007-02-16 2012-02-14 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US20090143288A1 (en) 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
SI2125894T1 (sl) 2007-03-22 2019-05-31 Biogen Ma Inc. Vezavne beljakovine, vključno s protitelesi, derivati protiteles in fragmenti protiteles, ki specifično vežejo CD154, ter njihove uporabe
US8557588B2 (en) * 2007-03-27 2013-10-15 Schlumberger Technology Corporation Methods and apparatus for sampling and diluting concentrated emulsions
EP2068923A4 (en) 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5791895B2 (ja) 2007-05-04 2015-10-07 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー 遺伝子操作されたウサギ抗体可変ドメイン及びその使用
NZ741494A (en) 2007-05-14 2022-11-25 Kyowa Kirin Co Ltd Methods of reducing eosinophil levels
MX2009012282A (es) 2007-05-17 2009-11-25 Genentech Inc Estructuras cristalinas de fragmentos de neuropilina y complejos de neuropilina-anticuerpos.
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
EP2162469A4 (en) * 2007-05-21 2012-08-01 Alderbio Holdings Llc NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
HUE043782T2 (hu) 2007-05-21 2019-09-30 Alderbio Holdings Llc IL-6 elleni antitestek és alkalmazásuk
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
JP5718637B2 (ja) 2007-06-21 2015-05-13 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディおよびその使用
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
US8551751B2 (en) 2007-09-07 2013-10-08 Dyadic International, Inc. BX11 enzymes having xylosidase activity
SI2195023T1 (en) 2007-08-29 2018-07-31 Sanofi Humanized anti-CXCR5 antibodies, their derivatives and their uses
KR20100080519A (ko) 2007-08-30 2010-07-08 큐어디엠 인코포레이티드 프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법
WO2009029831A1 (en) * 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
WO2009039310A2 (en) 2007-09-18 2009-03-26 La Jolla Institute For Allergy And Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
CN101883790B (zh) 2007-10-05 2015-09-09 基因技术公司 抗淀粉样蛋白β抗体在眼病中的用途
US20100297012A1 (en) * 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009061818A1 (en) 2007-11-05 2009-05-14 Medimmune, Llc Methods of treating scleroderma
WO2009062112A2 (en) 2007-11-09 2009-05-14 The Salk Institute For Biological Studies Use of tam receptor inhibitors as antimicrobials
EP2586797A3 (en) 2007-11-27 2013-07-24 Medtronic, Inc. Humanized anti-amyloid beta antibodies
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
EP2796466B1 (en) 2007-12-07 2017-11-22 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
PL2222706T5 (pl) 2007-12-14 2017-09-29 Novo Nordisk As Przeciwciała przeciwko ludzkiemu NKG2D i ich zastosowania
EP2238169A1 (en) 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
NZ586544A (en) 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
DK2242772T3 (en) 2007-12-26 2015-01-05 Biotest Ag Immunoconjugates that targets CD138, and uses thereof
CA2710483C (en) 2007-12-26 2018-05-08 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells
CN101952315B (zh) 2007-12-26 2015-04-01 生物测试股份公司 靶向cd138的试剂及其应用
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
JP2011509650A (ja) * 2008-01-11 2011-03-31 株式会社ジーンテクノサイエンス ヒト化抗−α９インテグリン抗体及びその使用
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
ES2618292T3 (es) 2008-01-31 2017-06-21 Inserm - Institut National De La Sante Et De La Recherche Medicale Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
JP5608100B2 (ja) 2008-02-08 2014-10-15 メディミューン，エルエルシー 低下したＦｃリガンド親和性を有する抗ＩＦＮＡＲ１抗体
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CN102027016A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
WO2009121690A1 (en) 2008-03-13 2009-10-08 Biotest Ag Agent for treating disease
RU2540018C2 (ru) 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
EP2260102A1 (en) 2008-03-25 2010-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
EP2260863A1 (en) 2008-03-27 2010-12-15 Takara Bio, Inc. Prophylactic/therapeutic agent for infectious disease
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
DK2281005T3 (en) 2008-04-03 2014-02-24 Vib Vzw Single domain antibodies able to modulate bace1 activity
WO2009124931A2 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
EP2132228B1 (en) 2008-04-11 2011-06-22 Emergent Product Development Seattle, LLC Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
CN102027013B (zh) 2008-04-24 2015-01-14 株式会社遗传科技 细胞外基质蛋白的氨基酸序列rgd的特异性人源化抗体及其应用
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
EP2282773B1 (en) 2008-05-02 2014-01-15 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
KR101649189B1 (ko) 2008-05-09 2016-08-18 애브비 인코포레이티드 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
WO2009148964A2 (en) 2008-05-29 2009-12-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression and assembly of human group c rotavirus-like particles and uses thereof
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
AU2009256250B2 (en) 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
EP2303924B1 (en) 2008-06-16 2016-07-27 Patrys Limited Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
KR20190133077A (ko) 2008-06-25 2019-11-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
CA3020290A1 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
KR101882352B1 (ko) * 2008-06-25 2018-07-26 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
RU2559525C2 (ru) 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
NZ590074A (en) 2008-07-08 2012-12-21 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
EP2324852B1 (en) 2008-08-07 2015-07-08 Nagasaki University Therapeutic or prophylactic agent for generalized pain syndrome
MX2011002478A (es) 2008-09-07 2011-04-05 Glyconex Inc Anticuerpo anti-glucoesfingolipido tipo i extendido, derivados del mismo y su uso.
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
NZ591134A (en) 2008-10-01 2012-08-31 Micromet Ag Cross-species-specific (human and primate) bispecific single chain antibody that binds both cd3 (epsilon) epitope and prostate specific membrane antigen (pmsa)
US10981998B2 (en) 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
EP2355847A1 (en) 2008-10-07 2011-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
EP2350270B1 (en) 2008-10-24 2018-03-07 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Human ebola virus species and compositions and methods thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
US8642280B2 (en) 2008-11-07 2014-02-04 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2198884A1 (en) 2008-12-18 2010-06-23 Centre National de la Recherche Scientifique (CNRS) Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5
CN106432503B (zh) 2008-12-19 2020-03-06 宏观基因有限公司 共价双抗体及其用途
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
WO2010082134A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
KR101245929B1 (ko) 2009-01-20 2013-03-22 호메이욘 에이치. 자데흐 항체 매개된 골질 재생
TW201031421A (en) 2009-01-29 2010-09-01 Abbott Lab IL-1 binding proteins
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
MA33122B1 (fr) 2009-02-17 2012-03-01 Ucb Pharma Sa Molecules d'anticorps ayant une specificite pour ox40 humain
EP2398504B1 (en) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
GB0902916D0 (en) 2009-02-20 2009-04-08 Fusion Antibodies Ltd Antibody therapy
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US20110311521A1 (en) 2009-03-06 2011-12-22 Pico Caroni Novel therapy for anxiety
AU2010221993C1 (en) 2009-03-10 2015-07-09 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized K33N monoclonal antibody
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EP2408820A4 (en) * 2009-03-16 2013-01-23 Cephalon Australia Pty Ltd HUMANIZED ANTIBODIES WITH ANTITUMOR EFFECT
US20120064096A1 (en) 2009-03-17 2012-03-15 Universite De La Mediterranee BTLA Antibodies and Uses Thereof
WO2010110346A1 (ja) 2009-03-24 2010-09-30 独立行政法人理化学研究所 白血病幹細胞マーカー
EP2411412B1 (en) 2009-03-24 2015-05-27 Teva Biopharmaceuticals USA, Inc. Humanized antibodies against light and uses thereof
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
US8748581B2 (en) 2009-04-10 2014-06-10 Ablynx N.V. Anti-IL-6R polypeptides and pharmaceutical compositions thereof
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
RU2595379C2 (ru) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
CA2764432C (en) 2009-04-27 2017-10-24 Kyowa Hakko Kirin Co., Ltd. Interleukin-3 receptor alpha chain-binding antibody to treat leukemia
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
SG176095A1 (en) 2009-06-05 2011-12-29 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
EP2440934B1 (en) 2009-06-08 2014-07-16 Vib Vzw Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US8956614B2 (en) 2009-06-15 2015-02-17 Vib Vzw BACE1 inhibitory antibodies
EP2443150B1 (en) 2009-06-17 2015-01-21 AbbVie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
RS20120461A1 (en) 2009-07-02 2013-06-28 Musc Foundation For Research Development METHODS FOR STIMULATION OF LIVER REGENERATION
CN102711791A (zh) 2009-07-03 2012-10-03 比奥诺尔免疫有限公司 用于hiv疫苗组合物或作为诊断方法的hiv相关肽的组合或融合物
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
EP2464664B1 (en) 2009-08-13 2015-09-23 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (rsv) and methods of use
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
TWI465250B (zh) 2009-08-29 2014-12-21 Abbvie Inc 治療用之ｄｌｌ４結合蛋白質
EP2473851A1 (en) 2009-08-31 2012-07-11 Abbott Biotherapeutics Corp. Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
IN2012DN02737A (sv) 2009-09-01 2015-09-11 Abbott Lab
WO2011036118A1 (en) 2009-09-22 2011-03-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011044368A1 (en) 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
KR20140015139A (ko) 2009-10-15 2014-02-06 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
LT2488551T (lt) 2009-10-16 2018-10-25 Progastrine Et Cancers S.A R.L. Monokloniniai antikūnai prieš progastriną ir jų panaudojimas
EP2493926B1 (en) 2009-10-27 2020-03-11 UCB Biopharma SRL Function modifying nav 1.7 antibodies
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
CN102753580A (zh) 2009-10-28 2012-10-24 亚培生物医疗股份有限公司 抗egfr抗体及其用途
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
CA2774286A1 (en) 2009-10-30 2011-05-05 Abbott Biotherapeutics Corp. Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
MX2012005164A (es) 2009-11-05 2012-10-03 Cephalon Australia Pty Ltd Tratamiento de cancer que involucra genes kras o braf mutados.
EP2496604B1 (en) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies
WO2011066374A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
WO2011067420A1 (en) 2009-12-04 2011-06-09 Vib Vzw Arf6 as a new target for treating alzheimer's disease
CN102656190A (zh) 2009-12-08 2012-09-05 雅培股份有限两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
WO2011084496A1 (en) 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
BR112012015523A2 (pt) 2009-12-23 2017-04-18 4-Antibody Ag membros de ligação do citomegalovirus humano, composição contendo os mesmos, método de tratamento, moléculas de anticorpo, método de produção, molecular de ácido nucléico, célula hospedeira, e, método de neutralização do hcmv.
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US8900588B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
EP2542582A4 (en) 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
US9434716B2 (en) 2011-03-01 2016-09-06 Glaxo Group Limited Antigen binding proteins
EP2542578A1 (en) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c and brain cancers
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
JP5829672B2 (ja) 2010-03-24 2015-12-09 レ ラボラトワール セルヴィエ 結腸直腸及び胃腸癌の予防
WO2011117653A1 (en) 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
CA2796215C (en) 2010-04-14 2021-05-18 National Research Council Of Canada Compositions and methods for brain delivery of analgesic peptides
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
PT3202789T (pt) 2010-04-16 2020-06-16 Biogen Ma Inc Anticorpos anti-vla-4
US20130034543A1 (en) 2010-04-19 2013-02-07 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Modulating xrn1
EP2571532B1 (en) 2010-05-14 2017-05-03 Abbvie Inc. Il-1 binding proteins
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
EP2580239A1 (en) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mammalian sterile 20-like kinase 3
KR101834026B1 (ko) 2010-06-19 2018-03-02 메모리얼 슬로안-케터링 캔서 센터 항-ｇｄ2 항체
ES2706913T3 (es) 2010-06-25 2019-04-01 Univ Aston Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2591000B1 (en) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
WO2012010696A1 (en) 2010-07-23 2012-01-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for cancer management targeting co-029
KR101576174B1 (ko) 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
JP5964300B2 (ja) 2010-08-02 2016-08-03 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディおよびその使用
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
RS63063B1 (sr) 2010-08-19 2022-04-29 Zoetis Belgium S A Anti-ngf antitela i njihova upotreba
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2614080A1 (en) 2010-09-10 2013-07-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
EP2621955B1 (en) 2010-10-01 2018-01-17 National Research Council of Canada Anti-ceacam6 antibodies and uses thereof
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP2632949B1 (en) 2010-10-25 2017-09-13 National Research Council of Canada Clostridium difficile-specific antibodies and uses thereof
US9328160B2 (en) 2010-10-29 2016-05-03 Perseus Proteomics Inc. Anti-CDH3 antibody having high internalization capacity
US20140093506A1 (en) 2010-11-15 2014-04-03 Marc Buehler Anti-fungal-agents
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
MX361929B (es) 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
ES2847891T3 (es) 2010-11-23 2021-08-04 Vitaeris Inc Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
EP2655416A1 (en) 2010-12-20 2013-10-30 Medimmune Limited Anti-il-18 antibodies and their uses
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
RU2627171C2 (ru) 2010-12-21 2017-08-03 Эббви Инк. Il-1 альфа и бета биспецифические иммуноглобулины с двойными вариабельными доменами и их применение
DK2654789T3 (en) 2010-12-22 2018-09-03 Orega Biotech ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF
WO2012083370A1 (en) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
ME02734B (me) 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2012110500A1 (en) 2011-02-15 2012-08-23 Vib Vzw Means and methods for improvement of synaptic dysfunction disorders
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
WO2012118042A1 (ja) 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
CA2828347A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
PL3235508T3 (pl) 2011-03-16 2021-07-12 Sanofi Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v
CA2830442C (en) 2011-03-31 2019-09-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against icos and uses thereof
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CA2833019A1 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN107998388B (zh) 2011-05-02 2023-07-14 千禧制药公司 抗α4β7抗体的制剂
CN103890010B (zh) 2011-05-19 2017-04-19 法国国家健康医学研究院 抗‑人‑her3抗体及其用途
JP6145088B2 (ja) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
CN108329391A (zh) 2011-05-27 2018-07-27 埃博灵克斯股份有限公司 使用rankl结合肽抑制骨质吸收
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9309305B2 (en) 2011-06-10 2016-04-12 National Research Council Of Canada Anti-ricin antibodies and uses thereof
DK2718320T3 (en) 2011-06-10 2018-03-26 Medimmune Ltd ANTI-PSEUDOMONAS-PSL BINDING MOLECULES AND APPLICATIONS THEREOF
EP2723376B1 (en) 2011-06-22 2018-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
RU2014101707A (ru) 2011-06-22 2015-07-27 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
EP2543677A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543678A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
MX2014002762A (es) 2011-09-09 2014-07-30 Amgen Inc Uso de proteina c-met para predecir la eficacia de anticuerpos de factor de crecimiento de anti-hepatocitos (hgf) en pacientes con cancer esofagico y gastrico.
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
CN103958544B (zh) 2011-09-16 2018-04-24 Ucb医药有限公司 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体
AU2012310880B2 (en) 2011-09-21 2015-12-03 Fujirebio Inc. Antibody against affinity complex
CA2849705A1 (en) 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Modified albumin-binding domains and uses thereof to improve pharmacokinetics
JP6239517B2 (ja) 2011-10-10 2017-11-29 メディミューン リミテッド 関節リウマチの治療法
RU2014120981A (ru) 2011-10-24 2015-12-10 Эббви Инк. Иммунные связывающие агенты против склеростина
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
CA2853951A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
US9221907B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Anti-GPR49 monoclonal antibodies
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
EP2776565A1 (en) 2011-11-08 2014-09-17 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
CA2856216C (en) 2011-11-11 2021-01-12 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
EP2599496A1 (en) 2011-11-30 2013-06-05 Kenta Biotech AG Novel targets of Acinetobacter baumannii
CA2857721C (en) 2011-12-05 2022-05-31 X-Body, Inc. Pdgf receptor beta binding polypeptides
RU2632108C2 (ru) 2011-12-08 2017-10-02 Биотест Аг Применения иммуноконъюгатов, мишенью которых является cd138
US20150030602A1 (en) 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
US20140363448A1 (en) 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
US8865870B2 (en) 2012-01-20 2014-10-21 Genzyme Corporation Anti-CXCR3 antibodies and methods of use thereof
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
IL305223A (en) 2012-01-27 2023-10-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
CN108324943B (zh) 2012-02-10 2024-03-08 思进股份有限公司 Cd30+癌症的检测和治疗
US9663568B2 (en) 2012-02-15 2017-05-30 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
ES2640268T3 (es) 2012-02-15 2017-11-02 Novo Nordisk A/S Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
KR102367723B1 (ko) 2012-03-28 2022-02-28 사노피 브라디키닌 b1 수용체 리간드에 대한 항체
US20150266961A1 (en) 2012-03-29 2015-09-24 Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
JP6389166B2 (ja) * 2012-05-07 2018-09-12 トラスティーズ・オブ・ダートマス・カレッジ 抗ｂ７−ｈ６抗体、融合タンパク質、及びこれらを使用する方法
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
ES2766836T3 (es) 2012-05-15 2020-06-15 Eisai Inc Métodos para el tratamiento de cáncer gástrico
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
WO2013182662A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Vaccine
EP2864355B1 (en) 2012-06-25 2016-10-12 Orega Biotech Il-17 antagonist antibodies
WO2014001557A1 (en) 2012-06-28 2014-01-03 Ucb Pharma S.A. A method for identifying compounds of therapeutic interest
US20150218238A1 (en) 2012-06-29 2015-08-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
EP2869818A1 (en) 2012-07-06 2015-05-13 Novartis AG Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
US9765156B2 (en) 2012-07-13 2017-09-19 The Trustees Of The University Of Pennsylvania Enhancing activity of CAR T cells by co-introducing a bispecific antibody
BR112015001459B1 (pt) 2012-07-25 2023-02-14 Celldex Therapeutics, Inc Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9695247B2 (en) 2012-09-03 2017-07-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against ICOS for treating graft-versus-host disease
NO2760138T3 (sv) 2012-10-01 2018-08-04
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
RU2689674C2 (ru) 2012-10-15 2019-05-28 Медиммьюн Лимитед Антитела к бета-амилоиду
AU2013334451A1 (en) 2012-10-24 2015-06-04 National Research Council Of Canada Anti-Campylobacter jejuni antibodies and uses therefor
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
EP2733153A1 (en) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the preparation of immunoconjugates and uses thereof
US9605078B2 (en) 2012-11-16 2017-03-28 The Regents Of The University Of California Pictet-Spengler ligation for protein chemical modification
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
PT2922875T (pt) 2012-11-20 2017-05-31 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
EP2925779A1 (en) 2012-11-30 2015-10-07 Institut Pasteur Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
WO2014100483A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses
CA2896091C (en) 2012-12-21 2018-06-19 Amplimmune, Inc. Anti-h7cr antibodies
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
CN105007941B (zh) 2012-12-27 2019-01-25 赛诺菲 抗-lamp1抗体和抗体药物偶联物及其用途
AU2013375015A1 (en) 2013-01-28 2015-08-13 Evec Inc. Humanized anti-HMGB1 antibody or antigen-binding fragment thereof
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
UY35340A (es) 2013-02-20 2014-09-30 Novartis Ag Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123
CN111139256A (zh) 2013-02-20 2020-05-12 诺华股份有限公司 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
MY175418A (en) 2013-03-13 2020-06-24 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
EP3916103A1 (en) 2013-03-14 2021-12-01 Abbott Laboratories Hcv core lipid binding domain monoclonal antibodies
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
BR112015023355A8 (pt) 2013-03-14 2018-01-30 Abbott Lab antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
CA2906421C (en) 2013-03-14 2022-08-16 George J. Dawson Hcv antigen-antibody combination assay and methods and compositions for use therein
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
EP3216804A3 (en) 2013-03-15 2017-12-20 AbbVie Biotechnology Ltd. Anti-cd25 antibodies and their uses
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
JP2016514690A (ja) 2013-03-15 2016-05-23 アッヴィ バイオテクノロジー リミテッド 抗ｃｄ２５抗体およびそれらの使用
EP2970436B1 (en) 2013-03-15 2018-09-05 AbbVie Biotherapeutics Inc. Fc variants
EP2968545B1 (en) 2013-03-15 2019-03-06 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
EP3816625A1 (en) 2013-05-06 2021-05-05 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US10005839B2 (en) 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
JP6682426B2 (ja) 2013-05-24 2020-04-15 メディミューン，エルエルシー 抗ｂ７−ｈ５抗体およびその使用
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
AU2014283185B2 (en) 2013-06-21 2019-05-02 Innate Pharma Enzymatic conjugation of polypeptides
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
WO2015013671A1 (en) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
ES2761587T3 (es) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
PE20160244A1 (es) 2013-08-13 2016-05-10 Sanofi Sa Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
CN105722527A (zh) 2013-09-04 2016-06-29 国立大学法人大阪大学 用于治疗糖尿病的靶向dpp-4疫苗
US9481729B2 (en) 2013-09-11 2016-11-01 The University Of Hong Kong Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
JP6599338B2 (ja) 2013-09-16 2019-10-30 ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー） Ｈｂｖ感染および関連症状の治療のための免疫エフェクター細胞表面抗原およびｈｂｖ抗原結合性の二重特異性または多重特異性ポリペプチド
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
PT3021859T (pt) 2013-10-25 2018-03-09 Psioxus Therapeutics Ltd Adenovírus oncolíticos munidos de genes heterólogos
JP2016536018A (ja) 2013-10-28 2016-11-24 ドッツ テクノロジー コーポレイションＤＯＴＳ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐ． アレルゲン検出
CA2927099A1 (en) 2013-10-31 2015-05-07 Sanofi Specific anti-cd38 antibodies for treating human cancers
US10196455B2 (en) 2013-11-07 2019-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neuregulin allosteric anti-HER3 antibody
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US9493413B2 (en) 2013-11-27 2016-11-15 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US9944694B2 (en) 2013-12-13 2018-04-17 Rijksuniversiteit Groningen Antibodies against Staphylococcus aureus and uses therof
JP6685225B2 (ja) 2013-12-16 2020-04-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 形質細胞様樹状細胞の枯渇
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
SI3083680T1 (sl) 2013-12-20 2020-06-30 F. Hoffmann-La Roche Ag Humanizirana protitelesa proti beljakovini Tau(pS422) in postopki uporabe
CN106132433B (zh) 2013-12-27 2021-04-06 国立大学法人大阪大学 以il-17a作为靶标的疫苗
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
US11028143B2 (en) 2014-01-21 2021-06-08 Novartis Ag Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
UA120048C2 (uk) 2014-03-06 2019-09-25 Нешнл Рісеч Каунсіл Оф Канада Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r)
KR102355310B1 (ko) 2014-03-06 2022-01-24 내셔날 리서치 카운실 오브 캐나다 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도
JP6541236B2 (ja) 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
AU2015231155B2 (en) 2014-03-21 2020-11-12 X-Body, Inc. Bi-specific antigen-binding polypeptides
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
IL293603B2 (en) 2014-04-07 2024-03-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
EP3131929B1 (en) 2014-04-16 2022-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
US20170044257A1 (en) 2014-04-25 2017-02-16 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
KR102275513B1 (ko) 2014-04-30 2021-07-08 화이자 인코포레이티드 항-ptk7 항체-약물 접합체
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
NZ726513A (en) 2014-05-28 2023-07-28 Memorial Sloan Kettering Cancer Center Anti-gitr antibodies and methods of use thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
US10124070B2 (en) 2014-06-06 2018-11-13 Redwood Bioscience, Inc. Anti-HER2 antibody-maytansine conjugates and methods of use thereof
US20170137824A1 (en) 2014-06-13 2017-05-18 Indranil BANERJEE New treatment against influenza virus
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
EP3157535A1 (en) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
US20170165261A1 (en) 2014-07-01 2017-06-15 Brian Arthur Hemmings Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
KR20240029114A (ko) 2014-07-17 2024-03-05 노보 노르디스크 에이/에스 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
BR112017001579A2 (pt) 2014-07-25 2017-11-21 Cytomx Therapeutics Inc anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
CA2950381C (en) 2014-07-29 2021-02-23 Cellectis Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy
JP2017522893A (ja) 2014-07-31 2017-08-17 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｏｒ１特異的多重鎖キメラ抗原受容体
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
JP7084138B2 (ja) 2014-08-19 2022-06-14 ノバルティス アーゲー 癌処置に使用するための抗ｃｄ１２３キメラ抗原受容体（ｃａｒ）
WO2016036861A1 (en) 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
CA2959694C (en) 2014-09-04 2023-11-21 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
RS60305B1 (sr) 2014-09-05 2020-07-31 Janssen Pharmaceutica Nv Agensi koji vezuju cd123 i njihove upotrebe
WO2016043577A1 (en) 2014-09-16 2016-03-24 Academisch Medisch Centrum Ig-like molecules binding to bmp4
CA2961636A1 (en) 2014-09-17 2016-03-24 Boris ENGELS Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
WO2016044588A1 (en) 2014-09-19 2016-03-24 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
US10365280B2 (en) 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
US10098973B2 (en) 2014-10-10 2018-10-16 National Research Council Of Canada Anti-tau antibody and uses thereof
ES2822228T3 (es) 2014-10-24 2021-04-29 Univ Leland Stanford Junior Composiciones y métodos para inducir la fagocitosis de células positivas de clase I de CMH y contrarrestar la resistencia a anti-CD47/SIRPA
EP3215166B1 (en) 2014-10-31 2024-04-24 The Trustees of the University of Pennsylvania Altering gene expression in car-t cells and uses thereof
KR20230141922A (ko) 2014-10-31 2023-10-10 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 T 세포를 자극 및 증대시키는 조성물 및 방법
AU2015339012B2 (en) 2014-10-31 2020-11-05 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
AU2015344769B2 (en) 2014-11-12 2020-07-09 Allogene Therapeutics, Inc. Inhibitory chimeric antigen receptors
EP4183806A3 (en) 2014-11-12 2023-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
EP3227341A1 (en) 2014-12-02 2017-10-11 CeMM - Forschungszentrum für Molekulare Medizin GmbH Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
DK3029137T3 (en) 2014-12-06 2019-04-08 Gemoab Monoclonals Gmbh GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF
CN113209306A (zh) 2014-12-09 2021-08-06 艾伯维公司 具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物
RU2017123942A (ru) 2014-12-09 2019-01-11 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
MX2017007381A (es) 2014-12-11 2017-11-06 Inbiomotion Sl Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.
CA2971517A1 (en) 2014-12-19 2016-06-23 Universite De Nantes Anti il-34 antibodies
WO2016097408A1 (en) 2014-12-19 2016-06-23 Biotecnol Limited Fusion protein comprising three binding domains to 5t4 and cd3
EP3237450B1 (en) 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
CA2973266A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
CN107530423B (zh) 2015-01-14 2022-04-05 布里格姆及妇女医院股份有限公司 用抗lap单克隆抗体治疗癌症
EP4039710A3 (en) 2015-01-23 2022-10-19 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
BR112017015453A2 (pt) 2015-01-26 2018-01-23 Cellectis células imunes modificadas knockout para receptor de células t, dotadas de receptores quiméricos de antígeno, de ligação a cd123 para o tratamento de linfoma mieloide agudo recorrente/refratário ou neoplasia blástica de células dendríticas plasmacitoides
CA2975147A1 (en) 2015-01-31 2016-08-04 Yangbing Zhao Compositions and methods for t cell delivery of therapeutic molecules
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016128349A1 (en) 2015-02-09 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
CN114504652A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CN116064731A (zh) 2015-03-13 2023-05-05 哈佛学院院长及董事 使用扩增测定细胞
AU2016233309B2 (en) 2015-03-17 2021-11-18 Memorial Sloan Kettering Cancer Center Anti-MUC16 antibodies and uses thereof
US10744157B2 (en) 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
WO2016162368A1 (en) 2015-04-07 2016-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-invasive imaging of tumor pd-l1 expression
RU2021121771A (ru) 2015-04-08 2022-01-12 Новартис Аг Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3584260A1 (en) 2015-04-28 2019-12-25 Mitsubishi Tanabe Pharma Corporation Rgma binding protein and use thereof
JP2018515082A (ja) 2015-04-30 2018-06-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 代謝障害を処置するための抗ａｐ２抗体及び抗原結合剤
CA2984991A1 (en) 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine
JP7019423B2 (ja) 2015-05-06 2022-02-15 ヤンセン バイオテツク，インコーポレーテツド 前立腺特異的膜抗原（ｐｓｍａ）二重特異性結合剤及びその使用
KR20180015650A (ko) 2015-05-07 2018-02-13 아게누스 인코포레이티드 항-ox40 항체 및 이의 사용 방법
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
AR104718A1 (es) 2015-05-20 2017-08-09 Cellectis Receptores de antígenos quiméricos específicos de anti-gd3 para inmunoterapias contra el cáncer
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
EA039951B1 (ru) 2015-05-27 2022-03-31 Юсб Биофарма Спрл Ингибитор активности csf-1r, предназначенный для лечения или профилактики эпилепсии или болезни паркинсона, и фармацевтическая композиция на его основе
CA2987051A1 (en) 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN113929779A (zh) 2015-06-24 2022-01-14 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
NZ738058A (en) 2015-07-06 2021-07-30 UCB Biopharma SRL Tau-binding antibodies
JP2018525029A (ja) 2015-07-07 2018-09-06 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） ミオシン１８ａに対する特異性を有する抗体およびその使用
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
EP3331569A1 (en) 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
JP2018522907A (ja) 2015-08-11 2018-08-16 セレクティスＣｅｌｌｅｃｔｉｓ Ｃｄ３８抗原を標的とするためおよびｃｄ３８遺伝子を不活化するために操作された、免疫療法用の細胞
WO2017040195A1 (en) 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN108135932A (zh) 2015-08-28 2018-06-08 宾夕法尼亚大学董事会 表达嵌合细胞内信号传导分子的细胞的方法和组合物
MA48579A (fr) 2015-09-01 2020-03-18 Agenus Inc Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
KR20180067676A (ko) 2015-10-27 2018-06-20 유씨비 바이오파마 에스피알엘 항-il-17a/f 항체를 사용한 치료 방법
WO2017074774A1 (en) 2015-10-28 2017-05-04 Yale University Humanized anti-dkk2 antibody and uses thereof
WO2017072669A1 (en) 2015-10-28 2017-05-04 Friedrich Miescher Institute For Biomedical Research Tenascin-w and biliary tract cancers
AR106543A1 (es) 2015-11-02 2018-01-24 Netris Pharma Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
AU2016349152A1 (en) 2015-11-03 2018-06-14 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
US20190209697A1 (en) 2015-11-05 2019-07-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
IL302822A (en) 2015-11-12 2023-07-01 Seagen Inc Compounds interacting with glycans and methods of use
RS65120B1 (sr) 2015-11-25 2024-02-29 Immunogen Inc Farmaceutske formulacije i postupci za njihovu upotrebu
CA3006596A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. Anti-hulrrc15 antibody drug conjugates and methods for their use
AU2016365117A1 (en) 2015-11-30 2018-05-31 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
CN108430499B (zh) 2015-12-15 2022-07-19 肿瘤免疫股份有限公司 嵌合和人源化抗人类ctla4单克隆抗体和其用途
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
CN114705858A (zh) 2015-12-31 2022-07-05 Syncerus有限责任公司 用于评估癌症发生的风险的组合物和方法
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
CA3013333A1 (en) 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
DK3423838T3 (da) 2016-03-02 2024-02-05 Idexx Lab Inc Fremgangsmåde og sammensætninger til påvisning og diagnosticering af nyresygdom og peridontal sygdom
BR112018067679A2 (pt) 2016-03-04 2019-01-15 Novartis Ag células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
US20190262327A1 (en) 2016-03-15 2019-08-29 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
SI3219726T1 (sl) 2016-03-17 2021-02-26 Tillotts Pharma Ag Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
EP3430044A1 (en) 2016-03-17 2019-01-23 Numab Innovation AG Anti-tnf alpha -antibodies and functional fragments thereof
CN108884156B (zh) 2016-03-17 2021-10-01 努玛创新有限公司 抗TNFα抗体及其功能片段
PT3219727T (pt) 2016-03-17 2021-01-21 Tillotts Pharma Ag Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
EP3430042B1 (en) 2016-03-17 2023-05-24 Numab Innovation AG Anti-tnfalpha-antibodies and functional fragments thereof
EP3432925A4 (en) 2016-03-22 2019-11-06 Bionomics Limited ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
KR20230148844A (ko) 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
HRP20230457T1 (hr) 2016-04-15 2023-07-21 Novartis Ag Pripravci i postupci za selektivnu ekspresiju kimernih antigenskih receptora
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
EP3452506A1 (en) 2016-05-01 2019-03-13 UCB Biopharma SPRL Affinity engineered serum protein carrier binding domain
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
WO2017201204A1 (en) 2016-05-17 2017-11-23 Abbvie Biotherapeutics Inc. ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
WO2017201488A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017205465A2 (en) 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
EP3464362B1 (en) 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
MX2018014630A (es) 2016-05-27 2019-06-10 Abbvie Biotherapeutics Inc Anticuerpos anti-cd40 y sus usos.
SG11201810023QA (en) 2016-05-27 2018-12-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
EP3464375A2 (en) 2016-06-02 2019-04-10 Novartis AG Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
US20200002421A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3835322A3 (en) 2016-06-08 2021-10-06 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
PE20190510A1 (es) 2016-06-13 2019-04-10 I Mab Anticuerpos anti-pd-l1 y usos de los mismos
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
KR20190053835A (ko) 2016-06-21 2019-05-20 테네오바이오, 인코포레이티드 Cd3 결합 항체
MA45602A (fr) 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
CA3030841A1 (en) 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
AU2017295886C1 (en) 2016-07-15 2024-01-25 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
AU2017299854A1 (en) 2016-07-18 2019-01-31 Helix Biopharma Corp. CAR immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer
US20190151365A1 (en) 2016-07-28 2019-05-23 Novartis Ag Combination therapies of chimeric antigen receptors and pd-1 inhibitors
BR112019001693A2 (pt) 2016-07-29 2019-07-02 Ct Hospitalier Universitaire Toulouse anticorpos direcionados a macrófagos associados a tumores e seus usos
US20190161542A1 (en) 2016-08-01 2019-05-30 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
JP2020500834A (ja) 2016-08-26 2020-01-16 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ マクロファージ刺激タンパク質受容体（又はＲＯＮ（Ｒｅｃｅｐｔｅｕｒ ｄ′Ｏｒｉｇｉｎｅ Ｎａｎｔａｉｓ））抗体及びその使用
EP3503918B1 (en) 2016-08-29 2020-09-30 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
MX2019002946A (es) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
WO2018052503A1 (en) 2016-09-14 2018-03-22 Teneobio, Inc. Cd3 binding antibodies
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
US10647767B2 (en) 2016-09-19 2020-05-12 I-Mab Biopharma Co., Ltd. Anti-GM-CSF antibodies and uses thereof
BR112019005292A2 (pt) 2016-09-21 2019-09-03 Nextcure Inc anticorpos para siglec-15 e métodos de uso dos mesmos.
EP4360714A2 (en) 2016-09-21 2024-05-01 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
IL292551B2 (en) 2016-10-07 2023-10-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
CN117586403A (zh) 2016-10-11 2024-02-23 艾吉纳斯公司 抗lag-3抗体及其使用方法
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
MA46779A (fr) 2016-11-02 2019-09-11 Health Research Inc Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3535294A4 (en) 2016-11-07 2020-09-30 Neuracle Science Co., Ltd. ANTI-FAMILY WITH SEQUENCE LIKE 19, ELEMENT A5 ANTIBODY AND METHOD OF USING THEREOF
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
US11773163B2 (en) 2016-11-21 2023-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
BR112019010602A2 (pt) 2016-11-23 2019-12-17 Harpoon Therapeutics Inc proteínas trispecíficas para psma e métodos de uso
US10899842B2 (en) 2016-11-23 2021-01-26 Immunoah Therapeutics, Inc. 4-1BB binding proteins and uses thereof
CA3044659A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
MA50948A (fr) 2016-12-07 2020-10-14 Agenus Inc Anticorps et procédés d'utilisation de ceux-ci
SG10201914126RA (en) 2016-12-15 2020-02-27 Abbvie Biotherapeutics Inc Anti-ox40 antibodies and their uses
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
JP7254699B2 (ja) 2016-12-21 2023-04-10 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
JP2020504744A (ja) 2016-12-22 2020-02-13 サノフイＳａｎｏｆｉ 枯渇活性を有するヒト化ｃｘｃｒ３抗体およびその使用方法
TW201840585A (zh) 2016-12-22 2018-11-16 法商賽諾菲公司 用於白斑病的治療的抗人cxcr3抗體
CN110291105B (zh) 2017-01-05 2024-03-01 奈特里斯药物公司 导蛋白-1干扰药物和免疫检查点抑制剂药物的组合治疗
EP3565845A4 (en) 2017-01-06 2020-10-07 Biosion, Inc. ERBB2 ANTIBODIES AND THEIR USES
BR112019013238A2 (pt) 2017-01-20 2020-02-11 Tayu Huaxia Biotech Medical Group Co., Ltd. Anticorpos anti-pd-1 e usos dos mesmos
AU2018213549B2 (en) 2017-01-24 2022-02-03 I-Mab Biopharma Co., Ltd. Anti-CD73 antibodies and uses thereof
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
EP3577134A1 (en) 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3354278A1 (en) 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
CN110418652A (zh) 2017-02-07 2019-11-05 詹森生物科技公司 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
CA3051640A1 (en) 2017-03-16 2018-09-20 Innate Pharma Compositions and methods for treating cancer
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
CA3057841A1 (en) 2017-03-27 2018-10-04 Celgene Corporation Methods and compositions for reduction of immunogenicity
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
EP3609921A2 (en) 2017-04-13 2020-02-19 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
BR112019021472A8 (pt) 2017-04-14 2023-05-02 Inst Curie Compostos de ligação ao amhrii para prevenção ou tratamento de cânceres
MX2019012136A (es) 2017-04-14 2020-07-20 Gamamabs Pharma Compuestos de union al receptor de la hormona antimulleriana tipo ii (amhrii) para prevenir o tratar canceres de pulmon.
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
EP3615052B1 (en) 2017-04-27 2023-01-25 The University of Hong Kong Use of hcn inhibitors for treatment of cancer
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3618863B1 (en) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antibodies and methods of use thereof
EP3621640A4 (en) * 2017-05-10 2021-06-30 The Wistar Institute Of Anatomy And Biology OPTIMIZED NUCLEIC ACID ANTIBODIES CONSTRUCTIONS
SG11201909751TA (en) 2017-05-12 2019-11-28 Augusta University Research Institute Inc Human alpha fetoprotein-specific t cell receptors and uses thereof
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
JP7090347B2 (ja) 2017-05-12 2022-06-24 ハープーン セラピューティクス，インク． メソテリン結合タンパク質
KR20240042244A (ko) 2017-05-19 2024-04-01 신닥스 파마슈티컬스, 인크. 조합 요법
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
JP2020522512A (ja) 2017-05-31 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
CN111246867B (zh) 2017-06-01 2024-04-12 阿卡米斯生物公司 溶瘤病毒和方法
EP3630818A1 (en) 2017-06-02 2020-04-08 Ablynx NV Aggrecan binding immunoglobulins
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
WO2018232020A1 (en) 2017-06-13 2018-12-20 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR20200018498A (ko) 2017-06-20 2020-02-19 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
CN117567624A (zh) 2017-06-20 2024-02-20 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
EP3642229A1 (en) 2017-06-21 2020-04-29 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
US11613588B2 (en) 2017-06-28 2023-03-28 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
WO2019018647A1 (en) 2017-07-20 2019-01-24 Pfizer Inc. ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
WO2020159504A1 (en) 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
CN111491661A (zh) 2017-07-27 2020-08-04 诺莫坎制药有限责任公司 M(h)dm2/4的抗体及其在诊断和治疗癌症中的用途
US11680110B2 (en) 2017-07-31 2023-06-20 Hoffmann-La Roche Inc. Three-dimensional structure-based humanization method
CN111565750B (zh) 2017-08-28 2023-11-03 安吉克公司 抗tm4sf1抗体及其使用方法
CN111133005A (zh) 2017-09-07 2020-05-08 奥古斯塔大学研究所公司 程序性细胞死亡蛋白1抗体
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
ES2938609T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
JP7226833B2 (ja) 2017-09-21 2023-02-21 イムチェック セラピューティクス エスエーエス Ｂｔｎ２に特異性を有する抗体及びその使用
KR20210027230A (ko) 2017-10-04 2021-03-10 옵코 파마슈티칼스, 엘엘씨 암의 개인 맞춤형 치료에 관한 물품 및 방법
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
JP7356727B2 (ja) 2017-10-12 2023-10-05 慶應義塾 アクアポリン３（ａｑｐ３）の細胞外ドメインに特異的に結合する抗ａｑｐ３モノクローナル抗体、及びその使用
BR112020007196A2 (pt) 2017-10-13 2020-12-01 Harpoon Therapeutics, Inc. proteínas triespecíficas e métodos de uso
CR20200195A (es) 2017-10-13 2020-08-14 Harpoon Therapeutics Inc Proteínas de unión a antigenos de maduraciòn de celulas b
WO2019089594A1 (en) 2017-10-31 2019-05-09 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CA3082365A1 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
KR20200087176A (ko) 2017-11-14 2020-07-20 아르셀엑스, 인크. 다기능성 면역 세포 요법
JP7165193B2 (ja) 2017-11-27 2022-11-02 パーデュー、ファーマ、リミテッド、パートナーシップ ヒト組織因子を標的とするヒト化抗体
MX2020006715A (es) 2017-12-27 2020-08-20 Teneobio Inc Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
WO2019161439A1 (en) 2018-02-23 2019-08-29 Cartherics Pty. Ltd. T cell disease treatment targeting tag-72
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
AU2019234213A1 (en) 2018-03-12 2020-09-03 Zoetis Services Llc Anti-NGF antibodies and methods thereof
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
AR117566A1 (es) 2018-04-02 2021-08-18 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y sus usos
WO2019197651A1 (en) 2018-04-12 2019-10-17 Mediapharma S.R.L. Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
US20210230255A1 (en) 2018-04-27 2021-07-29 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
KR20200122409A (ko) 2018-05-10 2020-10-27 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
WO2019222130A1 (en) 2018-05-15 2019-11-21 Immunogen, Inc. Combination treatment with antibody-drug conjugates and flt3 inhibitors
AU2019274657A1 (en) 2018-05-24 2020-12-10 Janssen Biotech, Inc. PSMA binding agents and uses thereof
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
BR112020025661A2 (pt) 2018-06-18 2021-03-23 UCB Biopharma SRL antagonista anti-grem1, agente anticâncer, métodos de tratamento de um câncer e de prognosticar um câncer, composição ou kit, métodos para a detecção de câncer, para determinar se um paciente com ou com suspeita de ter ou com risco de desenvolver câncer é ou não susceptível de responder ao tratamento com um agente quimioterápico, e para determinar se um paciente com ou com suspeita de ter ou com risco de desenvolver câncer tem probabilidade de responder ao tratamento com um antagonista de grem1
WO2019243252A1 (en) 2018-06-18 2019-12-26 Innate Pharma Compositions and methods for treating cancer
WO2019244107A1 (en) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
WO2019246494A1 (en) 2018-06-21 2019-12-26 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
WO2020002592A1 (en) 2018-06-29 2020-01-02 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Traf2 inhibitors for use in the treatment of a cancer
US11884729B2 (en) 2018-06-29 2024-01-30 ApitBio, Inc Anti-L1CAM antibodies and uses thereof
AU2019301336B2 (en) 2018-07-10 2022-11-24 Mitsubishi Tanabe Pharma Corporation Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
AU2019306165A1 (en) 2018-07-20 2021-02-25 Pierre Fabre Medicament Receptor for vista
MX2021002225A (es) 2018-08-30 2021-07-16 Tcr2 Therapeutics Inc Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
US20220098613A1 (en) 2018-09-12 2022-03-31 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
AU2019342017A1 (en) 2018-09-18 2021-05-13 Merrimack Pharmaceuticals, Inc. Anti-TNFR2 antibodies and uses thereof
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CN112839957A (zh) 2018-09-28 2021-05-25 协和麒麟株式会社 Il-36抗体及其用途
US20220047633A1 (en) 2018-09-28 2022-02-17 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
CN112969503A (zh) 2018-10-03 2021-06-15 斯塔滕生物技术有限公司 对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
MA53903A (fr) 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
US20220025058A1 (en) 2018-11-06 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
WO2020118293A2 (en) 2018-12-07 2020-06-11 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
JP7444886B2 (ja) 2018-12-11 2024-03-06 キュー３２・バイオ・インコーポレーテッド 補体関連疾患のための融合タンパク質構築物
WO2020120786A1 (en) 2018-12-14 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
US20220289857A1 (en) 2018-12-20 2022-09-15 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
KR20210122243A (ko) 2019-01-31 2021-10-08 누맙 세러퓨틱스 아게 ＴＮＦα 및 ＩＬ-17Ａ에 대한 특이성을 가지는 다중 특이적 항체, ＩＬ-17Ａ를 표적화하는 항체, 그리고 이의 사용 방법
WO2020162452A1 (ja) 2019-02-04 2020-08-13 国立大学法人愛媛大学 ＣＡＲライブラリおよびｓｃＦｖの製造方法
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
EP3927371A1 (en) 2019-02-22 2021-12-29 Novartis AG Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
US20220098307A1 (en) 2019-02-22 2022-03-31 Wuhan Yzy Biopharma Co., Ltd. Modified fc fragment, antibody comprising same, and application thereof
EP3928790A4 (en) 2019-02-22 2023-01-11 Wuhan Yzy Biopharma Co., Ltd. CD3 ANTIGEN-BINDING FRAGMENT AND APPLICATION THEREOF
CA3130303A1 (en) 2019-02-26 2020-09-03 Rgenix, Inc. High-affinity anti-mertk antibodies and uses thereof
EP3930846A1 (en) 2019-03-01 2022-01-05 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
KR20220007041A (ko) 2019-03-20 2022-01-18 임체크 테라퓨틱스 에스에이에스 Btn2에 대한 특이성을 갖는 항체 및 이의 용도
EP3947446A1 (en) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
AU2020247175A1 (en) 2019-03-26 2021-10-14 Aslan Pharmaceuticals Pte Ltd Treatment employing anti-IL-13R antibody or binding fragment thereof
CN113874392A (zh) 2019-03-28 2021-12-31 丹尼斯科美国公司 工程化抗体
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
AR119746A1 (es) 2019-06-14 2022-01-05 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
CA3146381A1 (en) 2019-07-11 2021-01-14 Wuhan Yzy Biopharma Co., Ltd. Tetravalent symmetric bispecific antibodies
EP4004050A2 (en) 2019-07-30 2022-06-01 QLSF Biotherapeutics Inc. Multispecific binding compound that bind to lfrrc15 and cd3
US20220281967A1 (en) 2019-08-02 2022-09-08 Orega Biotech Novel il-17b antibodies
MX2022001882A (es) 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
BR112022003740A2 (pt) 2019-08-30 2022-05-31 Agenus Inc Anticorpos anti-cd96 e métodos de uso dos mesmos
US20220348650A1 (en) 2019-09-03 2022-11-03 Bio-Thera Solutions, Ltd. Anti-tigit immunosuppressant and application thereof
CN114729045A (zh) 2019-09-26 2022-07-08 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
EP4034560A1 (en) 2019-09-27 2022-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance antibodies and uses thereof
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
EP4041768A1 (en) 2019-10-09 2022-08-17 StCube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
EP3812008A1 (en) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
EP3825330A1 (en) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117 antibodies and methods of use thereof
JP2023503429A (ja) 2019-11-22 2023-01-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 白血病幹細胞を根絶することによる、急性骨髄性白血病の処置のための、アドレノメデュリン阻害剤
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
EP4072682A1 (en) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies having specificity to her4 and uses thereof
WO2021116277A1 (en) 2019-12-10 2021-06-17 Institut Pasteur New antibody blocking human fcgriiia and fcgriiib
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
AR120898A1 (es) 2019-12-26 2022-03-30 Univ Osaka Agente para tratar o prevenir neuromielitis óptica en fase aguda
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
US20230090552A1 (en) 2020-01-08 2023-03-23 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
EP4091632A1 (en) 2020-01-15 2022-11-23 Osaka University Agent for prevention or treatment of diabetic autonomic neuropathy
EP4091633A1 (en) 2020-01-15 2022-11-23 Osaka University Prophylactic or therapeutic agent for dementia
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
CN115397848A (zh) 2020-02-05 2022-11-25 拉利玛生物医药公司 Tat肽结合蛋白及其用途
US20230125234A1 (en) 2020-02-13 2023-04-27 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
US20230096030A1 (en) 2020-02-13 2023-03-30 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
WO2021160266A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
US20230151108A1 (en) 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137
EP4103612A1 (en) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispecific antibodies against cd9
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
CN115515643A (zh) 2020-02-28 2022-12-23 建新公司 用于优化的药物缀合的经修饰的结合多肽
WO2021175954A1 (en) 2020-03-04 2021-09-10 Imcheck Therapeutics Sas Antibodies having specificity for btnl8 and uses thereof
CN115315446A (zh) 2020-03-06 2022-11-08 Go医疗股份有限公司 抗糖-cd44抗体及其用途
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
EP4130035A1 (en) 2020-03-31 2023-02-08 Bio-Thera Solutions, Ltd. Antibody and fusion protein for treating coronaviruses and use thereof
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
KR20230005257A (ko) 2020-04-24 2023-01-09 사노피 항-ceacam5 항체 접합체 및 folfiri를 함유하는 항종양 병용물
JP2023522395A (ja) 2020-04-24 2023-05-30 サノフイ 抗ｃｅａｃａｍ５抗体コンジュゲートおよびフォルフォックスを含有する抗腫瘍組み合わせ
US20230181755A1 (en) 2020-04-24 2023-06-15 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
US20230149557A1 (en) 2020-04-24 2023-05-18 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and cetuximab
CN113637082A (zh) 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
CN115894703A (zh) 2020-04-29 2023-04-04 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
EP4149558A1 (en) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
EP3915641A1 (en) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
JP2023529211A (ja) 2020-06-11 2023-07-07 ノバルティス アーゲー Ｚｂｔｂ３２阻害剤及びその使用
US20230272386A1 (en) 2020-07-17 2023-08-31 Mitsubishi Tanabe Pharma Corporation Agent for preventing or treating muscular disease
JP2023537022A (ja) 2020-08-07 2023-08-30 バイオ－テラ ソリュ－ションズ，エルティーディー． 抗ｐｄ－ｌ１抗体及びその応用
US20240010749A1 (en) 2020-09-04 2024-01-11 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
MX2023004020A (es) 2020-10-07 2023-07-07 Zoetis Services Llc Anticuerpos anti-ngf y métodos para su uso.
EP3981789A1 (en) 2020-10-12 2022-04-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Anti-lilrb antibodies and uses thereof
IL301859A (en) 2020-10-15 2023-06-01 UCB Biopharma SRL Binding molecules for CD45 multimerization
WO2022081436A1 (en) 2020-10-15 2022-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
JP2023545447A (ja) 2020-10-16 2023-10-30 キューエルエスエフ バイオセラピューティクス， インコーポレイテッド Ｐｄ－ｌ１に結合する多重特異性結合化合物
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
US20230406924A1 (en) 2020-11-02 2023-12-21 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
JP2023551113A (ja) 2020-11-06 2023-12-07 バイオ－テラ ソリュ－ションズ，エルティーディー． 二重特異性抗体及びその応用
EP4240494A1 (en) 2020-11-06 2023-09-13 Novartis AG Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
KR20230104651A (ko) 2020-11-06 2023-07-10 노파르티스 아게 Cd19 결합 분자 및 이의 용도
CA3198447A1 (en) 2020-11-13 2022-05-19 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
MX2023006426A (es) 2020-12-01 2023-07-17 Aptevo Res & Development Llc Antígenos asociados a tumores y proteínas de unión a cd3 y composiciones y métodos relacionados.
PE20231953A1 (es) 2020-12-07 2023-12-06 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos
AR124250A1 (es) 2020-12-07 2023-03-01 UCB Biopharma SRL Anticuerpos
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022143794A1 (zh) 2020-12-30 2022-07-07 百奥泰生物制药股份有限公司 抗cldn18.2抗体及其制备方法和应用
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
JP2024503658A (ja) 2021-01-13 2024-01-26 メモリアル スローン－ケタリング キャンサー センター 抗ｄｌｌ３抗体－薬物コンジュゲート
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022159575A1 (en) 2021-01-20 2022-07-28 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
JP2024505600A (ja) 2021-02-03 2024-02-06 モーツァルト セラピューティクス， インコーポレイテッド 結合剤およびそれを使用する方法
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
JP2024508157A (ja) 2021-03-04 2024-02-22 センター ナショナル デ ラ レシェルシェ サイエンティフィーク 炎症、線維症及び肺疾患を治療するためのペリオスチン抗体の使用
JP2024512324A (ja) 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
JP2024511078A (ja) 2021-03-17 2024-03-12 レセプトス エルエルシー 抗ｉｌ－１３抗体を用いてアトピー性皮膚炎を処置する方法
BR112023019205A2 (pt) 2021-03-26 2023-10-24 Janssen Biotech Inc Anticorpos humanizados contra tau de filamento helicoidal pareado e usos dos mesmos
EP4067381A1 (en) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Novel tnfr2 binding molecules
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
AR125732A1 (es) 2021-05-03 2023-08-09 UCB Biopharma SRL Anticuerpos anti-trem1
US20220372168A1 (en) 2021-05-04 2022-11-24 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
WO2022235940A1 (en) 2021-05-06 2022-11-10 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
EP4355778A1 (en) 2021-06-17 2024-04-24 Boehringer Ingelheim International GmbH Novel tri-specific binding molecules
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
AU2022304582A1 (en) 2021-06-29 2024-02-01 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
KR20240040068A (ko) 2021-07-29 2024-03-27 다케다 야쿠힌 고교 가부시키가이샤 메조텔린을 특이적으로 표적화하는 조작된 면역 세포 및 이의 용도
CA3226537A1 (en) 2021-07-29 2023-02-02 Ana HENNINO Humanized anti-human .beta.ig-h3 protein and uses thereof
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
WO2023012343A1 (en) 2021-08-06 2023-02-09 Institut Du Cancer De Montpellier Methods for the treatment of cancer
AU2022325950A1 (en) 2021-08-11 2024-02-22 Viela Bio, Inc. Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
TW202325733A (zh) 2021-09-03 2023-07-01 美商Ｇｏ治療公司 抗醣化-lamp1抗體及其用途
AU2022339667A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023051663A1 (zh) 2021-09-30 2023-04-06 百奥泰生物制药股份有限公司 抗b7-h3抗体及其应用
GB202115122D0 (en) 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023075702A1 (en) 2021-10-29 2023-05-04 Aslan Pharmaceuticals Pte Ltd Anti-il-13r antibody formulation
CA3237142A1 (en) 2021-11-05 2023-05-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
WO2023097024A1 (en) 2021-11-24 2023-06-01 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
AR128222A1 (es) 2022-01-07 2024-04-10 Johnson & Johnson Entpr Innovation Inc MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
TW202337905A (zh) 2022-02-23 2023-10-01 新加坡商亞獅康私人有限公司 抗il13r抗體之糖基化形式
TW202346354A (zh) 2022-03-09 2023-12-01 德商馬克專利公司 抗ceacam5抗體及其結合物及用途
WO2023172968A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
TW202345899A (zh) 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(三)
TW202346355A (zh) 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(二)
WO2023170291A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
EP4245772A1 (en) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1 antibody to treat liver inflammation
EP4249509A1 (en) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1 antibody against arthritis-associated pain
WO2023186968A1 (en) 2022-03-29 2023-10-05 Netris Pharma Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023239803A1 (en) 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
GB202210679D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-12rb2
GB202210680D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-35r
WO2024018426A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
WO2024043837A1 (en) 2022-08-26 2024-02-29 Aslan Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
WO2024050354A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen binding antibodies and uses thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024054157A1 (en) 2022-09-06 2024-03-14 Aslan Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
WO2024062072A2 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062082A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062076A1 (en) 2022-09-21 2024-03-28 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
GB202214132D0 (en) 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4353253A1 (en) 2022-10-10 2024-04-17 Charité - Universitätsmedizin Berlin Purification of tcr-modified t cells using tcr-specific car-nk cells

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4695459A (en) * 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
WO1989007452A1 (en) * 1988-02-12 1989-08-24 Medical Research Council Improvements in or relating to antibodies
EP0365209A3 (en) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US5062934A (en) * 1989-12-18 1991-11-05 Oronzio Denora S.A. Method and apparatus for cathodic protection
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
CZ282603B6 (cs) * 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
DE07006112T1 (de) * 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
JPH06202412A (ja) * 1992-12-26 1994-07-22 Canon Inc 画像形成装置
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5535089A (en) * 1994-10-17 1996-07-09 Jing Mei Industrial Holdings, Ltd. Ionizer

Also Published As

Publication number Publication date
ATE124459T1 (de) 1995-07-15
DE69022982T2 (de) 1996-03-28
US20050202529A1 (en) 2005-09-15
KR100198478B1 (en) 1999-06-15
NO913228D0 (no) 1991-08-19
NO316076B1 (no) 2003-12-08
WO1991009967A1 (en) 1991-07-11
US5929212A (en) 1999-07-27
FI913927A0 (fi) 1991-08-20
GB2246570B (en) 1994-05-11
JPH11243955A (ja) 1999-09-14
BR9007197A (pt) 1992-01-28
NO913271D0 (no) 1991-08-20
HU912751D0 (en) 1992-01-28
FI990875A (sv) 1999-04-19
NO913229L (no) 1991-10-21
AU7033091A (en) 1991-07-24
EP0460178A1 (en) 1991-12-11
EP0626390A1 (en) 1994-11-30
ATE159299T1 (de) 1997-11-15
KR920701465A (ko) 1992-08-11
GB2246781A (en) 1992-02-12
AU649645B2 (en) 1994-06-02
NO985468L (no) 1991-10-21
EP0626390B1 (en) 2001-11-14
AU664801B2 (en) 1995-11-30
NO985467D0 (no) 1998-11-23
EP0460167B1 (en) 1995-10-11
HUT58824A (en) 1992-03-30
US20040071693A1 (en) 2004-04-15
DE69033857T2 (de) 2002-09-12
DE69020544D1 (de) 1995-08-03
GB9117611D0 (en) 1991-10-02
DE69022982D1 (de) 1995-11-16
GB2268744A (en) 1994-01-19
GB2268744B (en) 1994-05-11
CA2037607C (en) 2005-05-24
JP3452062B2 (ja) 2003-09-29
CA2037607A1 (en) 1992-09-07
CA2050479C (en) 1997-03-25
ES2112270T3 (es) 1998-04-01
GB2246781B (en) 1994-05-11
DK0460171T3 (da) 1995-08-28
FI108917B (sv) 2002-04-30
US7244615B2 (en) 2007-07-17
DE69033857D1 (de) 2001-12-20
GR3017734T3 (en) 1996-01-31
US20040202662A1 (en) 2004-10-14
ATE208794T1 (de) 2001-11-15
US7241877B2 (en) 2007-07-10
HU217693B (hu) 2000-03-28
EP0460167A1 (en) 1991-12-11
JPH05500312A (ja) 1993-01-28
US7244832B2 (en) 2007-07-17
HU215383B (hu) 2000-03-28
AU7048691A (en) 1991-07-24
ES2079638T3 (es) 1996-01-16
FI913926A0 (fi) 1991-08-20
EP0620276A1 (en) 1994-10-19
JPH04505398A (ja) 1992-09-24
GB9318911D0 (en) 1993-10-27
NO913229D0 (no) 1991-08-19
GB8928874D0 (en) 1990-02-28
FI109768B (sv) 2002-10-15
GB9117612D0 (en) 1991-11-20
DE69031591T2 (de) 1998-03-12
RU2112037C1 (ru) 1998-05-27
AU6974091A (en) 1991-07-24
US20040076627A1 (en) 2004-04-22
DE69031591D1 (de) 1997-11-20
US7262050B2 (en) 2007-08-28
AU646009B2 (en) 1994-02-03
HUT60786A (en) 1992-10-28
ZA9110129B (en) 1993-06-23
CA2046904C (en) 2003-12-02
GR3025781T3 (en) 1998-03-31
HU912752D0 (en) 1992-01-28
DK0460167T3 (da) 1995-11-20
FI108777B (sv) 2002-03-28
RO114298B1 (ro) 1999-03-30
NO913271L (no) 1991-08-20
US20050136054A1 (en) 2005-06-23
ES2074701T3 (es) 1995-09-16
GB2246570A (en) 1992-02-05
EP0460178B1 (en) 1997-10-15
CA2050479A1 (en) 1991-06-22
BG60462B1 (bg) 1995-04-28
FI913932A0 (fi) 1991-08-20
KR100197956B1 (ko) 1999-06-15
HUT58372A (en) 1992-02-28
KR100191152B1 (ko) 1999-06-15
NO913228L (no) 1991-10-21
NO316074B1 (no) 2003-12-08
NO985467L (no) 1991-10-21
DK0626390T3 (da) 2002-03-11
DE69020544T2 (de) 1996-01-18
ATE129017T1 (de) 1995-10-15
US20060073137A1 (en) 2006-04-06
JP3242913B2 (ja) 2001-12-25
CA2046904A1 (en) 1991-06-22
AU6461294A (en) 1994-12-22
EP0460171A1 (en) 1991-12-11
AU631481B2 (en) 1992-11-26
DK0460178T3 (da) 1997-12-22
FI108776B (sv) 2002-03-28
RO114232B1 (ro) 1999-02-26
ES2165864T3 (es) 2002-04-01
EP0460171B1 (en) 1995-06-28
NO985468D0 (no) 1998-11-23
US20050123534A1 (en) 2005-06-09
NO310560B1 (no) 2001-07-23
WO1991009966A1 (en) 1991-07-11
US20060029593A1 (en) 2006-02-09
WO1991009968A1 (en) 1991-07-11
RO114980B1 (ro) 1999-09-30
US20060073136A1 (en) 2006-04-06
JPH04506458A (ja) 1992-11-12

Similar Documents

Publication Publication Date Title
FI990875A0 (sv) CD4-specifik rekombinantantikropp